230 related articles for article (PubMed ID: 33903973)
1. Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model.
Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY
Cancer Immunol Immunother; 2021 Dec; 70(12):3541-3555. PubMed ID: 33903973
[TBL] [Abstract][Full Text] [Related]
2. The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing.
Hu HJ; Liang X; Li HL; Du CM; Hao JL; Wang HY; Gu JF; Ni AM; Sun LY; Xiao J; Hu JQ; Yuan H; Dai YS; Jin XT; Zhang KJ; Liu XY
Cell Death Dis; 2020 Nov; 11(11):1022. PubMed ID: 33257647
[TBL] [Abstract][Full Text] [Related]
3. Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models.
Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY
Hum Gene Ther; 2021 Dec; 32(23-24):1481-1494. PubMed ID: 34155929
[TBL] [Abstract][Full Text] [Related]
4. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
5. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
6. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
7. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
8. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
9. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
[TBL] [Abstract][Full Text] [Related]
10. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Zamarin D; Holmgaard RB; Subudhi SK; Park JS; Mansour M; Palese P; Merghoub T; Wolchok JD; Allison JP
Sci Transl Med; 2014 Mar; 6(226):226ra32. PubMed ID: 24598590
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
12. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
Zheng JN; Pei DS; Mao LJ; Liu XY; Sun FH; Zhang BF; Liu YQ; Liu JJ; Li W; Han D
Cancer Gene Ther; 2010 Jan; 17(1):28-36. PubMed ID: 19498459
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Jiang G; Sun C; Li RH; Wei ZP; Zheng JN; Liu YQ
J Cancer Res Clin Oncol; 2015 Jan; 141(1):75-85. PubMed ID: 25103017
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
18. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
[TBL] [Abstract][Full Text] [Related]
19. Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice.
He B; Huang X; Liu X; Xu B
Mol Biol Rep; 2013 Sep; 40(9):5397-405. PubMed ID: 23666064
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy.
Robert C
Trends Mol Med; 2017 Nov; 23(11):983-985. PubMed ID: 29137714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
